Hofseth Biocare ASA
The answer first
Does Hofseth Biocare beat the market?
No, Hofseth Biocare has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 2% of Nordic stocks
- Quality15
- Value8
- Trend19
No. 76 of 78 in consumer defensive
Max for seven days
Follow Hofseth Biocare with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Hofseth Biocare
Your first answer is free, no account needed.
Do you own Hofseth Biocare, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Hofseth Biocare and a few more. Free, no card.
Super Stock+46.4%In short
- Hofseth Biocare has fallen 38.2% over the past year, including dividends.
- Overall, Hofseth Biocare ranks better than 2% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 83.2%. The price is 90.4% below its peak now.
Who owns Hofseth Biocare? See the major shareholders and their stakes
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 2% of Nordic stocks.
No. 76 of 78 in consumer defensive
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 65 of 79 in consumer defensiveTypical in consumer defensive: 42Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity−59.29
- Asset turnoverSales divided by everything the company owns0.75
- Return on equityProfit divided by equity−444.6%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 75 of 78 in consumer defensiveTypical in consumer defensive: 55Typical in the Nordics: 50
- P/BPrice divided by equitynegative earnings
- P/SPrice divided by sales1.9
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 63 of 79 in consumer defensiveTypical in consumer defensive: 48Typical in the Nordics: 50
- 3 months−19.8%
- 6 months−18.6%
- 9 months−19.8%
- 12 months−38.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Hofseth Biocare
Hofseth Biocare ASA is a company in consumer defensive, listed on Oslo Børs. By market value, Hofseth Biocare is number 21 of 25 companies in consumer defensive on Oslo Børs. Hofseth Biocare has not paid a dividend in the past twelve months. Of the three measures in the ranking, Hofseth Biocare is strongest on trend, better than 19% of Nordic stocks. The share trades in NOK. It has around 78 employees.
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.


See the full analysis of Hofseth Biocare.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card